Development and research improved Incrementally Modified Drug(IMD) and generic products
- Development of new product through differentiated formulation technology
- Preformulation and formulation design with Quality by Design (QbD) / Scale-up / technology transfer
Work out taking measurements, making experiments and charting results of ongoing projects.
- Improvement of accuracy and simplifying the existing analytical methods
- Developing, verifying and establishing analytical method of new materials
JLP-1207 is a combination of solifenacin succinate and tamsulosin. Jeil has completed phase I study and phase Ⅲ is in progress. JLP-1310 is a combination of metformin hydrochloride and rosuvastatin calcium. Jeil completed phase I and phase Ⅲ study. JLP-1401 is a combination of telmisartan and amlodipine besylate and rosuvastatin calcium. Jeil completed phase I and phase Ⅲ study. JLP-1607 is a salt change IMD of Champix. Jeil has completed clinical and licensing. It is third grade medical device used for liver cancer chemoembolization. Jeil has completed biosafety, pilot clinic, certificate of GMP and pivotal clinic study is in progress. We have licensed Telmiduo, Seviduo, Solinacin, and have been licensed to Sevikar HCT, Trajenta, Trajenta duo, Brilinta. - Delayed controlled release pellet
- Controlled release combination pellet (DR+IR)
- Sustained release pellet - Taste-masking
- Pellet for Oral disintegrating tablet(ODT) or oral disintegrating particle - Double-layered tablet (IR+SR)
- Sustained release tablet
- Immediate release tablet - Dosage change (granule->tablet) - Lyophilization
- Solid dispersion
- Spray dryer #709, Yongin Technovalley A, 357, Guseong-ro, Giheung-gu, Yongin-si, Gyeonggi-do, 16914, Korea